2nd P-CAB Fexclu to be released into the 800 bil market

By Chon, Seung-Hyun | translator Alice Kang

22.06.29 06:00:55

가나다라 0

Daewoong’s Fexclu to be listed for reimbursement next month… 28% cheaper than K-CAB

Will rise as a variable in the PPI class and P-CAB class drug prescription market worth ₩800 billion

Industry’s expectations on Fexclu’s success rise due to its marketability that was verified by K-CAB and Daewoong’s sales power

Daewoong Pharmaceutical’s new drug, ‘Fexclu’ will be released next month. The industry’s eyes are on whether the drug will raise a storm in the PPI class and P-CAB class antiulcer medication prescription market that is estimated to be worth over ₩800 billion. The industry is also eyeing competition between Fexclu and K-CAB abroad.

◆Fexclu to be applied reimbursement from next month… prepares to target the ₩800 billion PPI·P-CAB market

According to industry sources on the 29th, Daewoong Pharmaceutical’s Fexclu will be listed for NHI reimbursement starting next month. With the reimbursement approval, the drug will be released in the market 6 months after it receiv

Chon, Seung-Hyun(1000@dailypharm.com)

If you want to see the full article, please JOIN US (click)